Antiresorptive therapy

Antiresorptive therapy has been studied in 13 papers since 2016: 5 observational studies in people, 8 reviews; 9 in the past year. The newest story, Nov 12, 2026: “Calcium, vitamin D not tied to less bone loss on aromatase inhibitors”.

Intervention

13 papers study it6 findingsUpdated

3 new papers in 30 daysSee all 13 papers on antiresorptive therapy

At a glance

The findings reach people, from one lab or study. 3 independent labs in 2 countries.

“Over a mean 4.2 years of follow-up, 3.7% new AT users and 4.2% non-users had diabetes (adjusted hazard ratio 1.01, 95% confidence interval 0.87-1.16).”
Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort studyDiabetes, obesity & metabolism2016doi:10.1111/dom.12678

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • Funders: Amgen and 1 more
  • Humans5

What did studies of antiresorptive therapy find?

3

Studies of antiresorptive therapy measured 3 outcomes: bone mass, alveolar bone loss and diabetes mellitus.

Bone mass

upin humans1

1 study
  1. Antiresorptive therapy improves bone mass in breast cancer survivors.

    “Timely initiation of anti-resorptive medication can help improve bone mass, reduce the incidence of fractures, and improve quality of life.”

    Reviewin breast cancer survivors

    Bone Health Assessment and Management among Survivors of Non-metastatic Breast Cancer: A Narrative Review

    Indian journal of endocrinology and metabolism

Alveolar bone loss

downin humans1

1 study
  1. Antiresorptive therapy protects against alveolar bone loss in humans.

    “Antiresorptive therapies may preserve alveolar bone”

    Reviewalveolar bone

    Osteoporosis and Periodontal Diseases: Exploring Shared Pathways, Bidirectional Links, and Integrated Management in a Narrative Review

    Cureus

More on Alveolar bone loss

Diabetes mellitus

no changein humans1HR 1.01

1 study
  1. Antiresorptive therapy was not clearly linked with diabetes mellitus in humans (adjusted HR 1.01 (95% CI 0.87–1.16); 3.7% new AT users vs 4.2% non-users).

    “Over a mean 4.2 years of follow-up, 3.7% new AT users and 4.2% non-users had diabetes (adjusted hazard ratio 1.01, 95% confidence interval 0.87-1.16).”

    Humansmean 4.2 years of follow-upfemalesn = 33,640

    Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort study

    Diabetes, obesity & metabolism

More on Diabetes mellitus

What is antiresorptive therapy linked with?

3

Studies link antiresorptive therapy with 3 measures: lumbar spine bone mineral density, bone fracture and hip fracture.

Lumbar spine bone mineral density

upin humans1

1 study
  1. Antiresorptive therapy is associated with lumbar spine bone mineral density in humans (Adjusted 5-year difference: +17.5 percentage points (95% CI 16.1 to 18.8); p < 0.001).

    “antiresorptive therapy was associated with BMD gain irrespective of baseline T-score.”

    HumansPostmenopausal patients with hormone receptor-positive breast cancer receiving adjuvant aromatase inhibitor therapy; compared with no supplementationzoledronate or denosumablumbar spine5 yearsfemalesn = 636

    Calcium, vitamin D not tied to less bone loss on aromatase inhibitors

    Journal of bone oncology

More on Lumbar spine bone mineral density

Bone fracture

downin humans1

1 study
  1. Antiresorptive therapy lowers the risk of bone fracture in breast cancer survivors.

    “Timely initiation of anti-resorptive medication can help improve bone mass, reduce the incidence of fractures, and improve quality of life.”

    Reviewin breast cancer survivors

    Bone Health Assessment and Management among Survivors of Non-metastatic Breast Cancer: A Narrative Review

    Indian journal of endocrinology and metabolism

More on Bone fracture

Hip fracture

downin humans1−2.6% patients

1 study
  1. Hip fracture is associated with antiresorptive therapy in humans (fragility hip fracture) (2.64% of patients).

    “however, only 2.64% of patients were given pharmacological therapy”

    Humansfragility hip fracture

    Hip Fractures in Malta: Are we Missing an Opportunity?

    Surgery journal (New York, N.Y.)

More on Hip fracture

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 0Sep 2026: 1Oct 2026: 2Nov 2026: 18 papers in 12 months
Journal of Bone Oncology

Calcium, vitamin D not tied to less bone loss on aromatase inhibitors

Over five years, spine bone density fell 11.1% with calcium and vitamin D and 11.4% without supplements in postmenopausal women taking breast cancer hormone therapy.Over five years, spine bone density fell 11.1% with calcium and vitamin D and 11.4% without supplements in postmenopausal women taking breast cancer hormone therapy.

Cohort · 636 peopleBone loss

See all 13 papers on antiresorptive therapy